Search results for: 'china cell ad g01e therapy industry development waste pfrs'

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

18 Oct 2024  |  Global  |  Market Research

Image-guided Therapy Market, Global, 2024-2029

Increased Demand for Minimally Invasive Procedures and the Surge in Day Surgeries at Outpatient Facilities are Driving Transformational Growth

Infographics

×

The image-guided therapy (IGT) market is growing rapidly, mainly driven by the rising preference for minimally invasive procedures, technological advancements in multimodal imaging, artificial intelligence, the use of software solutions that enable better clinical outcomes, and the high demand for precision medicine in oncology treatment. In additi...

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.

24 Oct 2018  |  North America  |  Market Research

Growth Opportunities in the Global Cell Therapy Market, Forecast to 2025

A Robust Product Pipeline Creating Opportunities for Ground-breaking Combination Therapies is Set to Revolutionize the Global Cell Therapy Market

Infographics

×

Key Issues Addressed

The global pharmaceuticals industry is continuously evolving to meet the requirements of a changing disease landscape. With the increasing prevalence of chronic infectious diseases and cancer, market needs are shifting from traditional small molecules to novel large molecule therapies, with cell therapies dominating the space. This study presents a...

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule the...

With the growing need for better therapeutics, and the current patent cliff that is underway, therapies such as monoclonal antibodies, recombinant protein therapeutics and even vaccines for a whole host of indications are in high demand. Conventionally expression systems were utilized to aid in the development and production of these therapeutics...

Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are work...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...